ArticleCyborg and bionic systems (Washington, D.C.)2023
Engineering In vitro Models: Bioprinting of Organoids with Artificial Intelligence.
Article in Cyborg and bionic systems (Washington, D.C.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Pharmacokinetic profile of novel multi-layer stable effervescent tablet: a cross-over study with an established European brand in healthy young male adults.BMC pharmacology & toxicology · 2024Trial
- Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026Review
- The sixth sense of the brain: interoception in organoid study.Bone research · 2026Review
- Markerless augmented reality-guided endodontic microsurgery for improving accuracy and time efficiency in mandibular molar apical surgery: an in vitro study.BMC oral health · 2026Article
- Applications and limitations of pluripotent stem cell-derived liver organoids.Chinese medical journal · 2026Review
- Progressive Insights into 3D Bioprinting for Corneal Tissue Restoration.Advanced healthcare materials · 2026Review
- Synthetic and Tissue-Engineered Vascular Grafts: Current Status, Emerging Technologies, and Clinical Prospects.Reviews in cardiovascular medicine · 2025Review
- The Synergy of Artificial Intelligence and 3D Bioprinting: Unlocking New Frontiers in Precision and Tissue Fabrication.Advanced functional materials · 2025Article
- Innovative applications of 3D printing in personalized medicine and complex drug delivery systems.iScience · 2025Review
- Advancing Bioprinting Technology Utilizing Portable Bioprinters: From Various Device Designs to Dental Applications.Annals of biomedical engineering · 2025Review
- Machine learning-based prediction of unconfined compressive strength of organic-rich clay shales using hybrid destructive and non-destructive inputs.Scientific reports · 2025Article
- Bridging the Gap: Unlocking the Potential of Biofabrication for Applications in In Vitro Testing.Langmuir : the ACS journal of surfaces and colloids · 2025Review
- 3D Printing in Oral Drug Delivery: Technologies, Clinical Applications and Future Perspectives in Precision Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Engineered Tissue Models to Decode Host-Microbiota Interactions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Multiscale computational modeling of 3D printed continuous Fiber reinforced polymer composites.Scientific reports · 2025Article
- Review
- Tendon regeneration deserves better: focused review onFrontiers in bioengineering and biotechnology · 2025Review
- A Vascularized Multilayer Chip Reveals Shear Stress-Induced Angiogenesis in Diverse Fluid Conditions.Cyborg and bionic systems (Washington, D.C.) · 2025Article
- Machine learning driven optimization of compressive strength of 3D printed bio polymer composite material.PloS one · 2025Article
- Fabrication of collagen-based biomaterials for sports medicine application.Regenerative biomaterials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last decade, organoids have gained popularity for developing mini-organs to support advancements in the study of organogenesis, disease modeling, and drug screening and, subsequently, in the development of new therapies. To date, such cultures have been used to replicate the composition and functionality of organs such as the kidney, liver, brain, and pancreas. However, depending on the experimenter, the culture environment and cell conditions may slightly vary, resulting in different organoids; this factor significantly affects their application in new drug development, especially during quantification. Standardization in this context can be achieved using bioprinting technology-an advanced technology that can print various cells and biomaterials at desired locations. This technology offers numerous advantages, including the manufacturing of complex three-dimensional biological structures. Therefore, in addition to the standardization of organoids, bioprinting technology in organoid engineering can facilitate automation in the fabrication process as well as a closer mimicry of native organs. Further, artificial intelligence (AI) has currently emerged as an effective tool to monitor and control the quality of final developed objects. Thus, organoids, bioprinting technology, and AI can be combined to obtain high-quality in vitro models for multiple applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.